West Pharmaceutical Services
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of West Pharmaceutical Services generated cash of $776,500,000, which is more than the previous year. Cash used in financing activities reached the amount of -$459,600,000 last year. Net change in cash is therefore -$40,400,000.
Cash Flow
| 2014 | 182.9M | -104M | -30.8M |
|---|---|---|---|
| 2015 | 212.4M | -129.5M | -41.5M |
| 2016 | 219.4M | -175.8M | -113.9M |
| 2017 | 263.3M | -133.6M | -109M |
| 2018 | 288.6M | -100.8M | -80.7M |
| 2019 | 367.2M | -228M | -36.8M |
| 2020 | 472.5M | -179.5M | -137.1M |
| 2021 | 584M | -253.1M | -168.1M |
| 2022 | 724M | -288.2M | -293.6M |
| 2023 | 776.5M | -368.7M | -459.6M |
WST Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 894.3M | 762.6M | 615.5M | 439.1M | 337.4M | 235.9M | 203M | 274.6M | 255.3M | 230M |
Operating activities | ||||||||||
Net income | 593.4M | 585.9M | 661.8M | 346.2M | 241.7M | 206.9M | 150.7M | 143.6M | 95.6M | 127.1M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 137.3M | 120.6M | 122.3M | 109.1M | 103.4M | 104.4M | 96.7M | 90.7M | 89.9M | 90M |
Stock-based compensation expense | 23.3M | 23.7M | 37.5M | 34M | 24.4M | 15.1M | 16.1M | 19.5M | 29.6M | 18.6M |
| Deferred income tax benefit | 23.3M | 23.7M | 37.5M | 34M | 24.4M | 15.1M | 16.1M | 19.5M | 29.6M | 18.6M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 4M | -35.6M | -123.5M | -46.6M | -33.3M | -43.8M | -39.7M | -23.3M | -14.1M | -6.3M |
Inventories | -13.5M | -49.8M | -86.5M | -73.7M | -18.6M | -7M | -3.6M | -21.2M | -11.4M | -16.2M |
Accounts payable | 4.4M | -2.8M | 16.8M | 36.6M | 25.3M | 400K | 12.6M | 6.1M | 17.2M | -3.5M |
Cash generated by operating activities | 776.5M | 724M | 584M | 472.5M | 367.2M | 288.6M | 263.3M | 219.4M | 212.4M | 182.9M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -85.1M | 0 | 0 | -8.4M | 0 | -9.3M |
Investments In Property Plant And Equipment | -362M | -284.6M | -253.4M | -174.4M | -126.4M | -104.7M | -130.8M | -170.2M | -131.6M | -112.1M |
Acquisitions Net | 0 | 0 | -2.2M | 0 | -104M | 0 | -6M | 0 | 0 | 112.1M |
Cash generated by investing activities | -368.7M | -288.2M | -253.1M | -179.5M | -228M | -100.8M | -133.6M | -175.8M | -129.5M | -104M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 37.1M | 28.8M | 0 | 31.8M | 0 | 29.7M | 0 | 280.5M |
Payments for dividends | -57M | -54.1M | -51.1M | -48.1M | -45.1M | -42.1M | -39.1M | -35.8M | -32.4M | -29.1M |
Repurchases of common stock | -451.2M | -222.2M | -151.9M | -115.5M | -85.3M | -75.2M | -74.4M | -55.9M | -5.6M | -4.1M |
Repayments of term debt | -2.3M | -44.3M | -2.2M | -2.3M | 62.1M | -100K | -34.9M | -69.8M | -27.4M | -285.7M |
Cash used in financing activities | -459.6M | -293.6M | -168.1M | -137.1M | -36.8M | -80.7M | -109M | -113.9M | -41.5M | -30.8M |
Net Change In Cash | -40.4M | 131.7M | 147.1M | 176.4M | 101.7M | 101.5M | 32.9M | -71.6M | 19.3M | 25.3M |
Cash at end of period | 853.9M | 894.3M | 762.6M | 615.5M | 439.1M | 337.4M | 235.9M | 203M | 274.6M | 255.3M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |